Amanote Research
Register
Sign In
68Ga-Nota-Prgd2 PET/CT for Integrin Imaging in Patients With Lung Cancer
Journal of Nuclear Medicine
- China
doi 10.2967/jnumed.115.160648
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Nuclear Medicine
Radiology
Imaging
Date
October 1, 2015
Authors
K. Zheng
N. Liang
J. Zhang
L. Lang
W. Zhang
S. Li
J. Zhao
G. Niu
F. Li
Z. Zhu
X. Chen
Publisher
Society of Nuclear Medicine
Related search
PET Imaging of Angiogenesis After Myocardial Infarction/Reperfusion Using a One-Step Labeled Integrin-Targeted Tracer 18f-AlF-Nota-Prgd2
European Journal of Nuclear Medicine and Molecular Imaging
Medicine
Nuclear Medicine
Radiology
Imaging
Novel PET Imaging of Atherosclerosis With 68Ga-Labeled NOTA-Neomannosylated Human Serum Albumin
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
Quantitative Analysis and Comparison Study of [18F]AlF-Nota-Prgd2, [18F]FPPRGD2 and [68Ga]Ga-Nota-Prgd2 Using a Reference Tissue Model
PLoS ONE
Multidisciplinary
68Ga-Psma Ligand PET/CT in Patients With Prostate Cancer: How We Review and Report
Cancer Imaging
Nuclear Medicine
Radiology
Ultrasound Technology
Oncology
Radiological
Imaging
Medicine
Comparison of 68Ga-Psma-11 PET/CT With 11c-Acetate PET/CT in Re-Staging of Prostate Cancer Relapse
Scientific Reports
Multidisciplinary
Diagnostic Performance of 68Ga-Psma-11 (HBED-CC) PET/CT in Patients With Recurrent Prostate Cancer: Evaluation in 1007 Patients
European Journal of Nuclear Medicine and Molecular Imaging
Medicine
Nuclear Medicine
Radiology
Imaging
A Comparative 68Ga-Citrate and 68Ga-Chloride PET/CT Imaging of Staphylococcus Aureus Osteomyelitis in the Rat Tibia
Contrast Media and Molecular Imaging
Medicine
Nuclear Medicine
Radiology
Imaging
Comparison of [18F]DCFPyL and [68Ga]Ga-Psma-Hbed-Cc for PSMA-PET Imaging in Patients With Relapsed Prostate Cancer
Molecular Imaging and Biology
Cancer Research
Nuclear Medicine
Radiology
Imaging
Oncology
68Ga‐PSMA‐11 PET‐CT Study in Prostate Cancer Patients With Biochemical Recurrence and Non‐contributive 18F‐Choline PET‐CT: Impact on Therapeutic Decision‐making and Biomarker Changes
Prostate
Oncology
Urology
